To review the therapy of the restless legs syndromes or periodic movements in sleep.
Dopaminergic medications:
Levodopa (8 double-blind trials ranging from 1 to 4 weeks duration, 107 patients): inconsistent results with some studies reporting no significant difference between treatments and others favouring levadopa over placebo for some outcome measures. 7 clinical series reported that the emergence of rebound or augmentation was the greatest problem.
Opioids:
Two double blind RCTs with 18 patients compared oxycodone (reported benefit from oxycodone compared to placebo) and proxyphene (no difference from placebo).
Benzodiazepines: two double blind cross-over studies, 1 to 4 weeks duration, 12 patients studied RLS and reported inconsistent results.
3. Anticonvulsant medications: Carbamazepine: one double blind RCT of five weeks duration and 181 patients reported carbamazepine was significantly better than placebo. A large placebo effect was noted. One RCT cross-over with six patients had no statistical analyses.
Gabapentine: two open label series with 22 patients neither of which reported statistical analyses.
4. Medications drawn from other classes: Clonidine: two double blind RCT, duration from 3 days to 3 weeks, 20 patients both reported significant benefit from clonidine compared to placebo.
Iron: one case-control with 18 patients reported benefit only for patients with ferritin <= 45 mg/l. Two case series with 45 patients treated with iron in the form of intravenous iron, oral iron and blood transfusion reported benefit from iron.
Non pharmacological therapy: Cognitive therapy vs clonazepam: one study, 4 weeks duration, 16 patients. Statistics were not clearly presented.
